DE69841261D1 - Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz - Google Patents
Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenzInfo
- Publication number
- DE69841261D1 DE69841261D1 DE69841261T DE69841261T DE69841261D1 DE 69841261 D1 DE69841261 D1 DE 69841261D1 DE 69841261 T DE69841261 T DE 69841261T DE 69841261 T DE69841261 T DE 69841261T DE 69841261 D1 DE69841261 D1 DE 69841261D1
- Authority
- DE
- Germany
- Prior art keywords
- genetically modified
- tumored
- target bacteria
- reduced virulence
- mutant salmonella
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000894006 Bacteria Species 0.000 title 1
- 230000001018 virulence Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 241000607142 Salmonella Species 0.000 abstract 2
- 241000607149 Salmonella sp. Species 0.000 abstract 1
- 101100021843 Shigella flexneri lpxM1 gene Proteins 0.000 abstract 1
- 101100021844 Shigella flexneri lpxM2 gene Proteins 0.000 abstract 1
- 230000009036 growth inhibition Effects 0.000 abstract 1
- 101150060640 lpxM gene Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/879—Salmonella
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/926,636 US6080849A (en) | 1997-09-10 | 1997-09-10 | Genetically modified tumor-targeted bacteria with reduced virulence |
US09/149,832 US6447784B1 (en) | 1997-09-10 | 1998-09-08 | Genetically modified tumor-targeted bacteria with reduced virulence |
PCT/US1998/018701 WO1999013053A1 (en) | 1997-09-10 | 1998-09-09 | Genetically modified tumor-targeted bacteria with reduced virulence |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69841261D1 true DE69841261D1 (de) | 2009-12-10 |
Family
ID=25453492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69841261T Expired - Lifetime DE69841261D1 (de) | 1997-09-10 | 1998-09-09 | Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz |
Country Status (5)
Country | Link |
---|---|
US (5) | US6080849A (de) |
KR (1) | KR20010015577A (de) |
AT (1) | ATE447005T1 (de) |
DE (1) | DE69841261D1 (de) |
ZA (1) | ZA988289B (de) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5997881A (en) * | 1995-11-22 | 1999-12-07 | University Of Maryland, Baltimore | Method of making non-pyrogenic lipopolysaccharide or A |
US6207648B1 (en) * | 1997-07-24 | 2001-03-27 | Trustees Of Boston University | Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy |
US6080849A (en) * | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
WO1999013053A1 (en) * | 1997-09-10 | 1999-03-18 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
US6962696B1 (en) * | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
MXPA02003384A (es) * | 1999-10-04 | 2002-08-20 | Vion Pharmaceuticals Inc | Composiciones y metodos para atacar tumores y entrega de moleculas determinantes. |
US20020054865A1 (en) * | 2000-09-21 | 2002-05-09 | Minoru Fujimori | Anaerobic bacterium as a drug for cancer gene therapy |
US20030194798A1 (en) * | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
US7396822B2 (en) | 2001-05-24 | 2008-07-08 | Vaxiion Therapeutics, Inc. | Immunogenic minicells and methods of use |
EP1281767A3 (de) | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren |
US7015027B1 (en) | 2001-11-20 | 2006-03-21 | Mds (Canada) Inc. | Radiation therapy by accumulation of therapeutic radionuclides in tumor-targeting bacteria |
WO2003063593A1 (en) * | 2002-01-28 | 2003-08-07 | Vion Pharmaceuticals, Inc. | Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent |
US20030224369A1 (en) * | 2002-02-25 | 2003-12-04 | Surber Mark W. | Reverse screening and target identification with minicells |
US20030224444A1 (en) * | 2002-02-25 | 2003-12-04 | Sabbadini Roger A. | Antibodies to native conformations of membrane proteins |
US20030207833A1 (en) * | 2002-02-25 | 2003-11-06 | Neil Berkley | Pharmaceutical compositions with minicells |
US20040005700A1 (en) * | 2002-05-28 | 2004-01-08 | Surber Mark W. | Poroplasts |
EP1369491A1 (de) * | 2002-06-05 | 2003-12-10 | Aladar A. Szalay | Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe |
US20030228261A1 (en) * | 2002-06-05 | 2003-12-11 | Aladar Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
RU2376371C2 (ru) | 2003-06-18 | 2009-12-20 | Дженелюкс Корпорейшн | Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение |
US20070134214A1 (en) * | 2003-08-13 | 2007-06-14 | Feng Xu | Inactivated host cell delivery of polynucleotides encoding immunogens |
US7390646B2 (en) * | 2003-09-17 | 2008-06-24 | The Regents Of The University Of California | Bacterial vectors and methods of use thereof |
US20050112097A1 (en) * | 2003-11-26 | 2005-05-26 | Hinton Golden S. | Method for the treatment of cancer |
US20070298012A1 (en) * | 2003-12-16 | 2007-12-27 | Ivan King | Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules |
US20060002956A1 (en) * | 2004-04-05 | 2006-01-05 | Surber Mark W | Minicells as vaccines |
US20050244375A1 (en) * | 2004-04-29 | 2005-11-03 | Leonard Arnold S | Composition and method of cancer treatment |
AU2005327292B2 (en) | 2004-05-21 | 2010-11-04 | The Regents Of The University Of California | Method for enhancing production of isoprenoid compounds |
US20060003454A1 (en) * | 2004-07-02 | 2006-01-05 | Conjugon, Inc. | Non-dividing donor cells for gene transfer |
CA2586126C (en) | 2004-11-24 | 2016-06-28 | Yasunobu Kano | Novel shuttle vector |
CA2603453C (en) * | 2005-04-08 | 2015-01-27 | Yoshinori Hamaji | 5-fluorouracil-resistant bacteria and method for production thereof |
US20060270040A1 (en) * | 2005-05-26 | 2006-11-30 | Conjugon, Inc. | Compositions and methods for treating tissue |
AP3827A (en) | 2005-07-05 | 2016-09-30 | Univ California | Polynucleotides encoding isoprenoid modifying enzymes and methods of use thereof |
DK2027272T3 (en) * | 2006-05-24 | 2016-03-14 | Scarab Genomics Llc | Plasmid DNA PREPARATIONS AND METHODS FOR THE MANUFACTURE OF SAME |
MX284139B (es) | 2006-05-26 | 2011-02-18 | Amyris Biotechnologies Inc | Produccion de isoprenoides. |
TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
EP2066778B1 (de) | 2006-09-26 | 2016-01-27 | The Regents of The University of California | Herstellung von isoprenoiden und isoprenoidvorläufern |
US7998461B2 (en) * | 2007-11-15 | 2011-08-16 | University Of Massachusetts | Salmonella cancer therapeutics and related therapeutic methods |
EP2242516A1 (de) | 2008-01-11 | 2010-10-27 | Genelux Corporation | Verfahren und zusammensetzungen zum nachweis von bakterien und zur behandlung von erkrankungen und störungen |
US8647642B2 (en) | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
US20100330607A1 (en) * | 2009-06-24 | 2010-12-30 | Photoswitch Biosciences, Inc. | Photoswitch-enabled ion channel assay system |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
JP5926242B2 (ja) | 2010-05-10 | 2016-05-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | エンドリボヌクレアーゼ組成物およびその使用方法 |
EP2593796A4 (de) | 2010-07-16 | 2016-07-27 | Auckland Uniservices Ltd | Bakterielle nitroreduktase-enzyme und verfahren dafür |
DK2675474T3 (en) | 2011-02-15 | 2019-04-23 | Vaxiion Therapeutics Llc | THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES |
EP2764119A2 (de) | 2011-10-05 | 2014-08-13 | Genelux Corporation | Methoden zum nachweis der replikation oder kolonisierung eines biologischen therapiemittels |
JP6406581B2 (ja) | 2011-12-16 | 2018-10-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | オプシンポリペプチドおよびその使用法 |
WO2013128288A1 (en) * | 2012-02-27 | 2013-09-06 | Thelial Technologies S.A. | Monomeric bacterial actin adp-ribosyltransferases as cancer chemotherapeutics |
WO2013158265A1 (en) | 2012-04-20 | 2013-10-24 | Genelux Corporation | Imaging methods for oncolytic virus therapy |
US9127284B2 (en) | 2012-05-04 | 2015-09-08 | The University Of Hong Kong | Modified bacteria and their uses thereof for the treatment of cancer or tumor |
EP3539563A1 (de) | 2012-07-19 | 2019-09-18 | Redwood Bioscience, Inc. | Für cd22 spezifischer antikörper und verfahren zur verwendung davon |
KR102076384B1 (ko) | 2012-08-16 | 2020-02-11 | 아이피어리언 인코포레이티드 | 타우병증을 치료하는 방법 |
CA3124553A1 (en) | 2012-10-25 | 2014-05-01 | Bioverativ Usa Inc. | Anti-complement c1s antibodies and uses thereof |
PT2914291T (pt) | 2012-11-02 | 2022-05-05 | Bioverativ Usa Inc | Anticorpos anti-complemento c1s e suas utilizações |
US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
PL3007726T3 (pl) | 2013-06-10 | 2021-01-11 | Ipierian, Inc. | Metody leczenia tauopatii |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
EP3581580A1 (de) | 2014-03-28 | 2019-12-18 | The Board of Trustees of the Leland Stanford Junior University | Manipulierte lichtaktivierte anionenkanalproteine und verfahren zur verwendung davon |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
JP2018513681A (ja) | 2015-03-31 | 2018-05-31 | エクセリゲン サイエンティフィック, インコーポレイテッドExeligen Scientific, Inc. | 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系 |
EA201792080A1 (ru) | 2015-04-06 | 2018-03-30 | БИОВЕРАТИВ ЮЭсЭй ИНК. | Гуманизированные анти-c1s антитела и способы их применения |
US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
EP3344654B1 (de) | 2015-09-02 | 2020-10-21 | Immutep S.A.S. | Anti-lag-3-antikörper |
CR20180529A (es) | 2016-04-04 | 2019-03-21 | Bioverativ Usa Inc | Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada |
EA201990884A1 (ru) | 2016-10-12 | 2019-10-31 | АНТИ-C1s АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
CA3061718A1 (en) | 2017-04-27 | 2018-11-01 | Regents Of The University Of California | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives |
US11168326B2 (en) | 2017-07-11 | 2021-11-09 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
US11192944B2 (en) | 2017-10-11 | 2021-12-07 | Bioverativ Usa Inc. | Methods of inducing complement activity |
EP3762498A4 (de) | 2018-03-08 | 2022-03-09 | New Atlas Biotechnologies LLC | Verfahren zur herstellung von tryptaminen |
SG11202100023XA (en) | 2018-07-11 | 2021-01-28 | Actym Therapeutics Inc | Engineered immunostimulatory bacterial strains and uses thereof |
WO2020047161A2 (en) | 2018-08-28 | 2020-03-05 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
JP2022524951A (ja) | 2019-02-27 | 2022-05-11 | アクティム・セラピューティクス・インコーポレイテッド | 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌 |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
CN113692413A (zh) | 2019-04-02 | 2021-11-23 | 肯乔克蒂生物技术股份有限公司 | 外排泵-癌症抗原多特异性抗体以及与其相关的组合物、试剂、试剂盒和方法 |
IL292836A (en) | 2019-11-12 | 2022-07-01 | Actym Therapeutics Inc | Platforms for administering bacteria that stimulate the immune system and their use for administering therapeutic products |
WO2021113736A1 (en) | 2019-12-05 | 2021-06-10 | Massachusetts Institute Of Technology | Single-domain antibody to chloramphenicol |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
CN116529267A (zh) | 2020-06-04 | 2023-08-01 | 肯乔克蒂生物技术股份有限公司 | Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法 |
JP2023539454A (ja) | 2020-08-12 | 2023-09-14 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌ベースのワクチン、治療薬およびrnaデリバリープラットフォーム |
WO2023086796A2 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
WO2023114658A1 (en) | 2021-12-13 | 2023-06-22 | Kenjockety Biotechnology, Inc. | Anti-abcb1 antibodies |
WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
WO2023192869A1 (en) | 2022-03-28 | 2023-10-05 | University Of Massachusetts | Antigen delivering salmonella for use as a tumor homing beacon to refocus preexisting, vaccine generated t cells to combat cancer |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US29043A (en) * | 1860-07-10 | Improvement in cultivators | ||
JPS57142256A (en) | 1981-02-25 | 1982-09-02 | Kao Corp | Sanitary napkin |
US4436727A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
DE3486459D1 (de) * | 1983-09-26 | 1997-12-11 | Udo Dr Med Ehrenfeld | Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr |
CA1321962C (en) | 1985-03-20 | 1993-09-07 | Aizo Matsushiro | Dental caries preventive preparations and method for preparing said preparations |
JPH0696538B2 (ja) | 1985-12-19 | 1994-11-30 | 株式会社アドバンス | 抗発癌剤 |
JPH0761950B2 (ja) | 1986-10-17 | 1995-07-05 | 塩野義製薬株式会社 | 抗腫瘍剤 |
DE3735381A1 (de) | 1987-03-31 | 1989-05-03 | Boehringer Mannheim Gmbh | Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen |
GB8730037D0 (en) | 1987-12-23 | 1988-02-03 | Wellcome Found | Vaccines |
JPH01180830A (ja) | 1988-01-11 | 1989-07-18 | Kayaku:Kk | 抗腫瘍剤 |
EP0338679A3 (de) | 1988-03-24 | 1991-03-06 | Genentech, Inc. | Tumor Necrosis Faktor zur Behandlung von Blasenkrebs |
JPH0284172A (ja) | 1988-07-21 | 1990-03-26 | Smithkline Beckman Corp | 異種遺伝子の発現能を有し、組換え型ワクチンとして有用なサルモネラ形質転換体 |
GB8912330D0 (en) | 1989-05-30 | 1989-07-12 | Wellcome Found | Live vaccines |
JPH0376580A (ja) * | 1989-08-17 | 1991-04-02 | Japan Tobacco Inc | 大腸菌発現ベクターとそれを利用した抗ウイルス性タンパク質の製造方法 |
WO1991006317A1 (en) | 1989-11-03 | 1991-05-16 | Washington University | Cross-protective salmonella vaccines |
US5830702A (en) * | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
US5695983A (en) * | 1990-12-18 | 1997-12-09 | The General Hospital Corporation | Salmonella vaccines |
WO1992011361A1 (en) * | 1990-12-18 | 1992-07-09 | The General Hospital Corporation | Improved vaccines |
JP3415145B2 (ja) | 1991-03-05 | 2003-06-09 | ザ ウエルカム ファウンデーション リミテッド | 弱毒化細菌における組換えタンパク質の発現 |
IL101409A0 (en) | 1992-03-29 | 1992-11-15 | Era Masis Ltd | Method for the early diagnosis of cancer |
IL101410A0 (en) | 1992-03-29 | 1992-11-15 | Era Masis Ltd | Formulation for the treatment of cancer |
JPH06298657A (ja) | 1993-04-15 | 1994-10-25 | Nippon Shoji Kk | 免疫強化剤 |
CN1113647A (zh) | 1993-08-25 | 1995-12-20 | 株式会社大制药工场 | 心脏恢复剂 |
US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
WO1995009655A1 (en) | 1993-10-06 | 1995-04-13 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Treatment of tumors by genetic transformation of tumor cells with genes encoding negative selective markers and cytokines |
IT1270123B (it) * | 1994-10-05 | 1997-04-28 | Dompe Spa | Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia |
US6051237A (en) * | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
US6150170A (en) * | 1998-05-03 | 2000-11-21 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same |
US5877159A (en) | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
US5705151A (en) * | 1995-05-18 | 1998-01-06 | National Jewish Center For Immunology & Respiratory Medicine | Gene therapy for T cell regulation |
US6190657B1 (en) | 1995-06-07 | 2001-02-20 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
US5824538A (en) | 1995-09-06 | 1998-10-20 | The United States Of America As Represented By The Secretary Of The Army | Shigella vector for delivering DNA to a mammalian cell |
WO1997008955A1 (en) | 1995-09-06 | 1997-03-13 | Department Of The Army, Us Government | Bacterial delivery system |
GB9521568D0 (en) | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
WO1997018225A1 (en) | 1995-11-14 | 1997-05-22 | The General Hospital Corporation | Salmonella secreted proteins and uses thereof |
US5997881A (en) | 1995-11-22 | 1999-12-07 | University Of Maryland, Baltimore | Method of making non-pyrogenic lipopolysaccharide or A |
US6887483B2 (en) * | 1995-12-01 | 2005-05-03 | University Of Iowa Research Foundation | Non-toxic mutants of pathogenic gram-negative bacteria |
WO1997025061A1 (en) * | 1996-01-09 | 1997-07-17 | Bristol-Myers Squibb Company | De-myristolated lipopolysaccharide of gram-negative bacteria |
NZ331380A (en) | 1996-02-16 | 1999-06-29 | Janssen Pharmaceutica Nv | Body or hair cleansing compositions containing a pyrithione salt and ketoconazole or elubiol |
JP2000510842A (ja) | 1996-05-10 | 2000-08-22 | ファルマシア・アンド・アップジョン・カンパニー | 全身性細菌疾患の治療のための抗菌剤の局所投与 |
GB9621091D0 (en) * | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
TW373083B (en) | 1996-12-20 | 1999-11-01 | Corning Inc | Reflective coupling array for optical waveguide |
WO1998033923A1 (en) | 1997-01-30 | 1998-08-06 | Imperial College Of Science, Technology & Medicine | MUTANT msbB or htrB GENES |
AU6868198A (en) * | 1997-03-28 | 1998-10-22 | Jason C. Grove | Antimicrobial mediated bacterial dna delivery |
US6537558B2 (en) * | 1997-03-31 | 2003-03-25 | Megan Health, Inc. | Methods of producing and using virulence attenuated poxR mutant bacteria |
WO1999013053A1 (en) | 1997-09-10 | 1999-03-18 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
US6080849A (en) * | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
US6143551A (en) * | 1997-12-29 | 2000-11-07 | Schering Aktiengesellschaft | Delivery of polypeptide-encoding plasmid DNA into the cytosol of macrophages by attenuated listeria suicide bacteria |
US6593592B1 (en) * | 1999-01-29 | 2003-07-15 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device having thin film transistors |
US6962696B1 (en) * | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
MXPA02003384A (es) | 1999-10-04 | 2002-08-20 | Vion Pharmaceuticals Inc | Composiciones y metodos para atacar tumores y entrega de moleculas determinantes. |
EP1281767A3 (de) * | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren |
US20070298012A1 (en) * | 2003-12-16 | 2007-12-27 | Ivan King | Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules |
-
1997
- 1997-09-10 US US08/926,636 patent/US6080849A/en not_active Expired - Lifetime
-
1998
- 1998-09-08 US US09/149,832 patent/US6447784B1/en not_active Expired - Lifetime
- 1998-09-09 AT AT98946891T patent/ATE447005T1/de not_active IP Right Cessation
- 1998-09-09 DE DE69841261T patent/DE69841261D1/de not_active Expired - Lifetime
- 1998-09-09 KR KR1020007002535A patent/KR20010015577A/ko not_active Application Discontinuation
- 1998-09-10 ZA ZA988289A patent/ZA988289B/xx unknown
-
1999
- 1999-06-22 US US09/337,689 patent/US6475482B1/en not_active Expired - Fee Related
-
2002
- 2002-04-18 US US10/125,328 patent/US6923972B2/en not_active Expired - Fee Related
-
2005
- 2005-04-28 US US11/117,085 patent/US7514089B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20030170276A1 (en) | 2003-09-11 |
US6475482B1 (en) | 2002-11-05 |
US6923972B2 (en) | 2005-08-02 |
US6447784B1 (en) | 2002-09-10 |
US6080849A (en) | 2000-06-27 |
US20070009489A1 (en) | 2007-01-11 |
ZA988289B (en) | 1999-03-22 |
ATE447005T1 (de) | 2009-11-15 |
KR20010015577A (ko) | 2001-02-26 |
US7514089B2 (en) | 2009-04-07 |
US20020026655A1 (en) | 2002-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69841261D1 (de) | Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz | |
HK1033956A1 (en) | Genetically modified tumor-targeted bacteria with reduced virulence | |
DE69631423D1 (de) | Chinolone und deren therapeutische verwendung | |
FI964681A0 (fi) | Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt | |
WO1993008259A3 (en) | Inhibitors of dipeptidyl-aminopeptidase type IV | |
HUP9801826A2 (hu) | HER-2/neu-fehérje intracelluláris doménje, és alkalmazása malignitások megelőzésére és kezelésére | |
DK1005353T3 (da) | Farmaceutisk præparat omfattende Lactobacillus casei rhamnosus | |
FI961621A0 (fi) | Proteiini:farnesyylitranseraasin substituoidut tetra- ja pentapeptidi-inhibiittorit | |
BG107537A (en) | Method for the inhibition of human tnf alpha activity and its application | |
MX9800922A (es) | Quinolonas y su uso terapeutico. | |
BG102708A (en) | 4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparation | |
UA39158C2 (uk) | Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі | |
FI961976A0 (fi) | Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina | |
ATE230600T1 (de) | Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus | |
BR9805544A (pt) | Uso de um composto. | |
WO1996035784A3 (de) | Chromatin-regulatorgene | |
PT815087E (pt) | Derivados de fenilo trissubstituidos | |
DE69322166T2 (de) | Prüfung auf ein vielfache resistenz gegen antibiotika verursachendes operon | |
ES2184861T3 (es) | Compuestos peptidicos inhibidores de la liberacion de la metaloproteinasa y del tnf y su utilizacion terapeutica. | |
ES2187648T3 (es) | Metodo para la administracion de farmacos para terapia genica. | |
HK1024265A1 (en) | Mutants of streptococcal toxin c and methods of use | |
PT1294874E (pt) | Variantes de cd154 e as suas utilizacoes | |
ATE250030T1 (de) | Peptidverbindungen mit mmp- und tnf-hemmender wirkung | |
NZ515727A (en) | Aminotetralin derivative for the therapy of cardiovascular diseases | |
BR0016616A (pt) | Microrganismos atenuados para o tratamento de infecção |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |